
Advent France Biotechnology hires Horgan and Foussat

Advent France Biotechnology has appointed Anne Horgan as partner and Arnaud Foussat as operating partner.
Horgan joins Advent from Sofinnova Partners, where she worked as senior associate and associate between 2013-2017 with a focus on biopharmaceutical investments. Before that she worked at Cancer Research Technology between 2007-2013 as project and business development manager, and at Biovitrum Group between 2003-2007 as a scientist.
Arnaud Foussat, Advent France
Foussat previously worked at TxCell between 2004-2017. He held the positions of head of non-clinical research, vice-president of research, chief scientific officer and most recently senior vice-president.
The appointments follow the recent first close of Advent France Biotechnology Seed Fund I in April 2017 on €64.75m. Advent France Biotechnology has a partnership with Advent Life Sciences, a trans-Atlantic venture capital firm investing in life sciences groups based in the UK, France and the US. The relationship offers it access to a team of 15 investment managers.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater